The present invention relates to a frozen food product, a natural stabilizer, a method for producing a frozen food product, and a sieve system for forming beads of frozen food products. More specifically, the solution concerns cryogenic, natural, ice cream beads, shock-frozen in liquid gases used in cryogenics, adapted to typical cold chains with a temperature of ?10? C. to ?18? C., and cryogenic, natural, ice cream beads embedded in a homogeneous traditional natural ice cream mass.

The present invention relates to a frozen food product, a natural stabilizer, a method for producing a frozen food product, and a sieve system for forming beads of frozen food products. More specifically, the solution concerns cryogenic, natural, ice cream beads, shock-frozen in liquid gases used in cryogenics, adapted to typical cold chains with a temperature of ?10? C. to ?18? C., and cryogenic, natural, ice cream beads embedded in a homogeneous traditional natural ice cream mass.

In alternative embodiments, the invention provides a triple combination therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn's Disease and complications of Crohn's Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti-TNF? composition, or a composition capable of down-modulating TNF? activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.

Cold desserts incorporating gelatin-based (gummy) components are provided in this paper. In particular, stick-mounted cold desserts, edible-cone cold desserts, and container-served desserts with gelatin-based components are described. The gelatin-based components of these desserts are made from gelatin-based candy material that is specially-formulated for consumption at cold temperatures. The gelatin-based components may be used with other components of a cold dessert such as with flavored water ice, ice cream, sherbet, sorbet, and the like as described throughout this paper.

Isolated Lactobacillus strains are useful in preventing or delaying the development of Type 1 Diabetes (T1D). A probiotic composition comprising the Lactobacillus strains and use of the composition in T1D prevention are provided.

An oral delivery system for collagen peptides is described, suitable for administration to both human and non-human animals, characterized in that it comprise a frozen dessert and a collagen peptide, the total amount of collagen peptide in the delivery system being less than or equal to 20% by weight of the delivery system. A process for preparing the above oral delivery system is also described.

An oral delivery system for collagen peptides is described, suitable for administration to both human and non-human animals, characterized in that it comprise a frozen dessert and a collagen peptide, the total amount of collagen peptide in the delivery system being less than or equal to 20% by weight of the delivery system. A process for preparing the above oral delivery system is also described.

Methods of production of edible filamentous fungal biomat formulations are provided as standalone protein sources and/or protein ingredients in foodstuffs as well as a one-time use or repeated use self-contained biomat reactor comprising a container with at least one compartment and placed within the compartment(s), a feedstock, a fungal inoculum, a gas-permeable membrane, and optionally a liquid nutrient medium.

Methods of production of edible filamentous fungal biomat formulations are provided as standalone protein sources and/or protein ingredients in foodstuffs as well as a one-time use or repeated use self-contained biomat reactor comprising a container with at least one compartment and placed within the compartment(s), a feedstock, a fungal inoculum, a gas-permeable membrane, and optionally a liquid nutrient medium.

Methods of production of edible filamentous fungal biomat formulations are provided as standalone protein sources and/or protein ingredients in foodstuffs as well as a one-time use or repeated use self-contained biomat reactor comprising a container with at least one compartment and placed within the compartment(s), a feedstock, a fungal inoculum, a gas-permeable membrane, and optionally a liquid nutrient medium.